Patients who are sick can get acute respiratory distress syndrome, a disorder that progresses quickly. Breathing becomes difficult or impossible due to fluid leaks into the lungs, which is the main consequence of acute respiratory distress syndrome. Low blood oxygen is a symptom of a serious lung disease. Individuals who have acute respiratory distress syndrome typically have a comorbid condition that causes surfactant breakdown and fluid accumulation in the lungs' small air sacs. There are two types of causes for acute respiratory distress syndrome: lung damage that occur directly or indirectly. Pneumonia, aspiration, trauma, and other conditions are among the direct lung injuries.

Challenges: The primary reasons impeding the respiratory distress syndrome market's revenue growth are the scarcity of approved medications for the treatment of acute respiratory distress syndrome worldwide and the general lack of awareness of the illness. Because there aren't enough skilled specialists and they don't know about the existence of treatments for this sickness, the development of treatments for global respiratory distress syndrome could be hampered during this time. Medication licensed particularly for the treatment of ARDS is currently scarce. Furthermore, there is a dearth of knowledge regarding the syndrome itself among the public and medical specialists. The identification and treatment of ARDS patients may be delayed as a result, which is problematic.

The epidemic caused by COVID-19 influenced the world economy. Owing to the disease's high contagiousness and infectiousness throughout the pandemic and even in the years after it, acute respiratory distress syndrome rapidly progressed. The global market for ARDS treatments grew dramatically because of the COVID-19 pandemic. Regarding the ARDS market, this epidemic has been extremely beneficial. Being one of the main risk factors for developing ARDS, COVID-19 has not only led to an increase in ARDS cases but has also changed and advanced therapy and treatment management for ARDS cases due to the significant time and resource commitment made in the search for a COVID-19 vaccine and cure. 

The market data provided by the study by competitive landscape, revenue analysis, and market segments includes a detailed analysis of key market players, such as Armstrong Medical, Besmed Health Business Corp, Bayer AG, Drägerwerk AG & Co KGaA, EUROSETS, Fisher & Paykel Healthcare Limited, F. Hoffmann-La Roche Ltd, Getinge AB, LivaNova PLC, and Pfizer Inc.

By Type: Based on the Type, Global Acute Respiratory Distress Syndrome Market is segmented as; Diagnosis, Treatment.

By Cause: Based on the Cause, Global Acute Respiratory Distress Syndrome Market is segmented as; Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, Others.

By Route of Administration: Based on the Route of Administration, Global Acute Respiratory Distress Syndrome Market is segmented as; Oral, Parenteral, Intramuscular, Intravenous, Others.

By End-User Industry: Based on the End-User Industry, Global Acute Respiratory Distress Syndrome Market is segmented as; Hospitals, Specialty Clinics, Home Healthcare, Others.

By Distribution Channel: Based on the Distribution Channel, Global Acute Respiratory Distress Syndrome Market is segmented as; Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.